Developmental damage, increased lipid peroxidation, diminished cyclooxygenase-2 gene expression, and lowered prostaglandin E2 levels in rat embryos exposed to a diabetic environment.
Previous experimental studies suggest that diabetic embryopathy is associated with an excess of radical oxygen species (ROS), as well as with a disturbance of prostaglandin (PG) metabolism. We aimed to investigate the relationship between these pathways and used hyperglycemia in vitro (embryo culture for 24-48 h) and maternal diabetes in vivo to affect embryonic development. Subsequently, we assessed lipid peroxidation and gene expression of cyclooxygenase (COX)-1 and -2 and measured the concentration of prostaglandin E2 (PGE2) in embryos and membranes. Both hyperglycemia in vitro and maternal diabetes in vivo caused embryonic dysmorphogenesis and increased embryonic levels of 8-epi-PGF2alpha, an indicator of lipid peroxidation. Addition of N-acetylcysteine (NAC) to the culture medium normalized the morphology and 8-epi-PGF2alpha concentration of the embryos exposed to high glucose. Neither hyperglycemia nor diabetes altered COX-1 expression, but embryonic COX-2 expression was diminished on gestational day 10. The PGE2 concentration of day 10 embryos and membranes was decreased after exposure to high glucose in vitro or diabetes in vivo. In vitro addition of NAC to high glucose cultures largely rectified morphology and restored PGE2 concentration, but without normalizing the COX-2 expression in embryos and membranes. Hyperglycemia/diabetes-induced downregulation of embryonic COX-2 gene expression may be a primary event in diabetic embryopathy, leading to lowered PGE2 levels and dysmorphogenesis. Antioxidant treatment does not prevent the decrease in COX-2 mRNA levels but restores PGE2 concentrations, suggesting that diabetes-induced oxidative stress aggravates the loss of COX-2 activity. This may explain in part the antiteratogenic effect of antioxidant treatment.
Wentzel
P
P
Department of Medical Cell Biology, University of Uppsala, Biomedicum, Sweden. parri.wentzel@medcellbiol.uu.se
Welsh
N
N
Eriksson
U J
UJ
D000014:Abnormalities, Drug-Induced; D000818:Animals; D000013:Congenital Abnormalities / Q000209:etiology*; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D003921:Diabetes Mellitus, Experimental / Q000150:complications* / Q000503:physiopathology; D015237:Dinoprost / Q000031:analogs & derivatives / Q000378:metabolism; D015232:Dinoprostone / Q000378:metabolism*; D004622:Embryo, Mammalian / Q000033:anatomy & histology / Q000378:metabolism / Q000502:physiology*; D005314:Embryonic and Fetal Development / Q000502:physiology; D028441:F2-Isoprostanes; D005260:Female; D015870:Gene Expression / Q000502:physiology*; D007213:Indomethacin / Q000494:pharmacology; D007527:Isoenzymes / Q000235:genetics*; D008054:Lipid Peroxides / Q000378:metabolism; D008565:Membrane Proteins; D011247:Pregnancy; D011248:Pregnancy Complications / Q000503:physiopathology*; D011451:Prostaglandin-Endoperoxide Synthases / Q000235:genetics*; D051381:Rats; D017207:Rats, Sprague-Dawley
D028441:F2-Isoprostanes; D007527:Isoenzymes; D008054:Lipid Peroxides; D008565:Membrane Proteins; C075750:8-epi-prostaglandin F2alpha; D015237:Dinoprost; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2; D011451:Prostaglandin-Endoperoxide Synthases; C496513:Ptgs1 protein, rat; D015232:Dinoprostone; D007213:Indomethacin